Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 16/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 12/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30602837 | 0.96 | NTSR1 (0.55) | NTSR1NTSR2SORT1F2OPRD1 | |
| SCHEMBL30545296 | 0.95 | NTSR1 (0.53) | NTSR1NTSR2SORT1F2OPRD1 | |
| SCHEMBL31401995 | 0.91 | NTSR1 (0.56) | NTSR1NTSR2SORT1F2OPRM1 | |
| SCHEMBL29748654 | 0.88 | NTSR1 (0.50) | NTSR1NTSR2SORT1F2OPRD1 | |
| SCHEMBL29801725 | 0.87 | NTSR2 (0.57) | NTSR1NTSR2OPRD1OPRM1 | |
| SCHEMBL29904128 | 0.87 | APLNR (0.51) | NTSR1NTSR2SORT1F2OPRD1 | |
| SCHEMBL29904044 | 0.86 | OPRM1 (0.55) | OPRM1 | |
| SCHEMBL38655507 | 0.86 | OPRM1 (0.55) | OPRM1 | |
| SCHEMBL30917327 | 0.84 | NTSR1 (0.54) | NTSR1NTSR2SORT1F2 | |
| SCHEMBL29679546 | 0.84 | OPRD1 (0.60) | F2OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3529614-B1 | METHODS FOR IDENTIFYING A NON-HEALING SKIN WOUND AND FOR MONITORING THE HEALING OF A SKIN WOUND | AKRIBES BIOMEDICAL GMBH (AT) | 2026-05-06 | — | — | EP | disclosed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| CN-119119189-A | Polypeptides having MMP2 inhibitory effect | 大正制药株式会社 | 2024-12-13 | — | — | CN | disclosed |
| CN-114450294-B | Polypeptides having MMP2 inhibitory effect | 大正制药株式会社 | 2024-11-26 | — | — | CN | disclosed |
| US-20240199692-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-20 | — | — | US | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-11579141-B2 | Methods for identifying a non-healing skin wound and for monitoring the healing of a skin wound | AKRIBES BIOMEDICAL GMBH (AT) | 2023-02-14 | — | — | US | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20220412975-A1 | CHARACTERIZING MODULATORS OF ADAMTS-7 AND ADAMTS-12 | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-29 | — | — | US | disclosed |
| WO-2022265150-A1 | EXOSOME-RICH CULTURE MEDIUM OF IMMORTALIZED STEM CELLS AND FUNCTIONAL COMPOSITION COMPRISING BOTULINUM TOXIN | 충북대학교 산학협력단 | 2022-12-22 | — | — | WO | disclosed |
| EP-4104842-A1 | FUNCTIONAL COMPOSITION COMPRISING EXOSOME-RICH CONDITIONED MEDIUM OF IMMORTALIZED STEM CELLS AND BOTULINUM TOXIN | Chungbuk National University Industry-Academic Cooperation Foundation (KR) | 2022-12-21 | — | — | EP | disclosed |
| CN-115486537-A | Exosome-rich culture media comprising immortalized stem cells and functional compositions of botulinum toxin | 忠北大学校产学协力团 | 2022-12-20 | — | — | CN | disclosed |
| WO-2022234867-A1 | SULFONAMIDE HAVING MMP 7-INHIBITING ACTION | 大正製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4056581-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-09-14 | — | — | EP | disclosed |
| CN-114878550-A | Multifunctional health monitoring contact lens and preparation and detection method thereof | 温州医科大学 | 2022-08-09 | — | — | CN | disclosed |
| CN-109844529-B | Method for identifying non-healing skin wounds and for monitoring skin wound healing | 阿克里斯生物医药有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114450294-A | Polypeptide with MMP2 inhibitory effect | 大正制药株式会社 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199692-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | MMP2, MMP26, MMP25 | NTSR1 441/4885NTSR2 333/4885SORT1 452/4885 |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | NTSR1 1584/4885NTSR2 1794/4885SORT1 3559/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | NTSR1 682/4885NTSR2 1040/4885SORT1 3441/4885 |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAM17 | NTSR1 682/4885NTSR2 1040/4885SORT1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.